公开(公告)号：MX9704352A

公开(公告)日：1997-12-31

申请号：MX9704352

申请日：1997-06-12

Applicant: HOFFMANN LA ROCHE

Inventor： CIVELLI OLIVIER ,  MARTIN JAMES RICHARD ,  MONSMA FREDERICK ,  MOREAU JEAN-LUC ,  NOTHACKER HANS-PETER ,  REINSCHEID RAINER

IPC: G01N33/53 ,  A61K38/00 ,  A61K38/10 ,  A61P25/08 ,  A61P25/20 ,  A61P25/26 ,  G01N33/15 ,  G01N33/566 ,  G01N33/94 ,  A61B05/00

Abstract: La presente invencion se refiere a un método de escrutinio de un compuesto terapéuticamente util basado en el ensayo de agonista del receptor LC132 en un ensayo de escrutinio para transtornos neurologicos y/o psiquiátricos. Más específicamente, el método de escrutinio se basa en poner en contacto un receptor LC132 con un agente que se sospecha que es un agonista de la funcion del receptor LC132, seguido de la deteccion de la union y/o de la actividad agonista del compuesto, y seguido del ensayo de un agente con actividad agonista LC132 en un ensayo de escrutinio de actividad antiepiléptica, anticonvulsionante y/o ansiolítica.

公开(公告)号：AU2485397A

公开(公告)日：1997-12-18

申请号：AU2485397

申请日：1997-06-12

Applicant: HOFFMANN LA ROCHE

Inventor： CIVELLI OLIVIER ,  MARTIN JAMES RICHARD ,  MONSMA FREDERICK ,  MOREAU JEAN-LUC ,  NOTHACKER HANS-PETER ,  REINSCHEID RAINER

IPC: G01N33/53 ,  A61K38/00 ,  A61K38/10 ,  A61P25/08 ,  A61P25/20 ,  A61P25/26 ,  G01N33/15 ,  G01N33/566 ,  G01N33/94 ,  G01N33/68

Abstract: The present invention relates to a method of screening for a therapeutically useful compound which comprises testing an LC132 receptor agonist in a screening assay for psychiatric and/or neurological disorders. More particularly, the screening method is based on contacting an LC132 receptor with an agent suspected of being an agonist of the LC132 receptor function, followed by the detection of the binding and/or the agonist activity of the compound and then testing of an agent with LC132 agonist activity in an antiepileptic, anticonvulsant or anxiolytic screening assay.

公开(公告)号：AU769666B2

公开(公告)日：2004-01-29

申请号：AU5211400

申请日：2000-05-05

Applicant: HOFFMANN LA ROCHE

Inventor： JENCK FRANCOIS ,  HOFFMANN-EMERY FABIENNE ,  HUNKELER WALTER ,  MARTIN JAMES RICHARD ,  SLEIGHT ANDREW

IPC: A61K31/5513 ,  A61K31/5517 ,  A61P25/08 ,  A61P25/20 ,  A61P25/22 ,  C07D487/04

Abstract: The present invention relates to compound 7-Chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5-methyl-4,5-dihydro-imidazo[1,5-a][1,4]benzodiazepin-6-one (I)and to the use of the compound of formula I for the manufacture of medicaments to be used as anxiolytic and/or anticonvulsant and/or non-sedative sleep-inducing medicaments.

公开(公告)号：ZA200108913B

公开(公告)日：2003-03-26

申请号：ZA200108913

申请日：2001-10-29

Applicant: HOFFMANN LA ROCHE

Inventor： JENCK FRANCOIS ,  ANDREW HUNKELER WALTER SLEIGHT ,  HOFFMANN-EMERY FABIENNE ,  MARTIN JAMES RICHARD

IPC: A61K31/5513 ,  A61K31/5517 ,  A61P25/08 ,  A61P25/20 ,  A61P25/22 ,  C07D487/04 ,  C07D ,  A61K ,  A61P

Abstract: The present invention relates to compound 7-Chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5-methyl-4,5-dihydro-imidazo[1,5-a][1,4]benzodiazepin-6-one (I)and to the use of the compound of formula I for the manufacture of medicaments to be used as anxiolytic and/or anticonvulsant and/or non-sedative sleep-inducing medicaments.

公开(公告)号：BR0010495A

公开(公告)日：2002-02-13

申请号：BR0010495

申请日：2000-05-05

Applicant: HOFFMANN LA ROCHE

Inventor： JENCK FRANCOIS ,  HOFFMANN-EMERY FABIENNE ,  HUNKELER WALTER ,  MARTIN JAMES RICHARD ,  LEIGHT ANDREWS

IPC: A61K31/5513 ,  A61K31/5517 ,  A61P25/08 ,  A61P25/20 ,  A61P25/22 ,  C07D487/04

Abstract: The present invention relates to compound 7-Chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5-methyl-4,5-dihydro-imidazo[1,5-a][1,4]benzodiazepin-6-one (I)and to the use of the compound of formula I for the manufacture of medicaments to be used as anxiolytic and/or anticonvulsant and/or non-sedative sleep-inducing medicaments.

公开(公告)号：CA2372040A1

公开(公告)日：2000-11-23

申请号：CA2372040

申请日：2000-05-05

Applicant: HOFFMANN LA ROCHE

Inventor： JENCK FRANCOIS ,  HUNKELER WALTER ,  HOFFMANN-EMERY FABIENNE ,  SLEIGHT ANDREW ,  MARTIN JAMES RICHARD

IPC: A61K31/5513 ,  A61K31/5517 ,  A61P25/08 ,  A61P25/20 ,  A61P25/22 ,  C07D487/04 ,  C07D235/00 ,  C07D243/00

Abstract: The present invention relates to compound 7-Chlore-3- (5-dimethylaminomethyl - [1,2,4]oxadiazol- 3-yl)-5-methyl -4,5-dihydro -imidazo[1,5-a] [1,4]benzodiazepin -6-one (I), and to the use of the compound of formula (I) for the manufacture of medicaments to be used as anxiolytic and/or anticonvulsant and/or non-sedative sleep-inducing medicaments.

公开(公告)号：AU719519B2

公开(公告)日：2000-05-11

申请号：AU2485397

申请日：1997-06-12

Applicant: HOFFMANN LA ROCHE

Inventor： CIVELLI OLIVIER ,  MARTIN JAMES RICHARD ,  MONSMA FREDERICK ,  MOREAU JEAN-LUC ,  NOTHACKER HANS-PETER ,  REINSCHEID RAINER

IPC: G01N33/53 ,  A61K38/00 ,  A61K38/10 ,  A61P25/08 ,  A61P25/20 ,  A61P25/26 ,  G01N33/15 ,  G01N33/566 ,  G01N33/94 ,  G01N33/68

Abstract: The present invention relates to a method of screening for a therapeutically useful compound which comprises testing an LC132 receptor agonist in a screening assay for psychiatric and/or neurological disorders. More particularly, the screening method is based on contacting an LC132 receptor with an agent suspected of being an agonist of the LC132 receptor function, followed by the detection of the binding and/or the agonist activity of the compound and then testing of an agent with LC132 agonist activity in an antiepileptic, anticonvulsant or anxiolytic screening assay.

公开(公告)号：NZ328033A

公开(公告)日：1998-11-25

申请号：NZ32803397

申请日：1997-06-06

Applicant: HOFFMANN LA ROCHE

Inventor： CIVELLI OLIVIER ,  MARTIN JAMES RICHARD ,  MONSMA FREDERICK ,  MOREAU JEAN-LUC ,  NOTHACKER HANS-PETER ,  REINSCHEID RAINER

IPC: G01N33/53 ,  A61K38/00 ,  A61K38/10 ,  A61P25/08 ,  A61P25/20 ,  A61P25/26 ,  G01N33/15 ,  G01N33/566 ,  G01N33/94 ,  G01N33/68 ,  C07K14/435

Abstract: The present invention relates to a method of screening for a therapeutically useful compound which comprises testing an LC132 receptor agonist in a screening assay for psychiatric and/or neurological disorders. More particularly, the screening method is based on contacting an LC132 receptor with an agent suspected of being an agonist of the LC132 receptor function, followed by the detection of the binding and/or the agonist activity of the compound and then testing of an agent with LC132 agonist activity in an antiepileptic, anticonvulsant or anxiolytic screening assay.

公开(公告)号：CZ179597A3

公开(公告)日：1998-03-18

申请号：CZ179597

申请日：1997-06-11

Applicant: HOFFMANN LA ROCHE

Inventor： CIVELLI OLIVIER ,  MARTIN JAMES RICHARD ,  MONSMA FREDERICK ,  MOREAU JEAN LUC ,  NOTHACKER HANS PETER ,  REINSCHEID RAINER

IPC: G01N33/53 ,  A61K38/00 ,  A61K38/10 ,  A61P25/08 ,  A61P25/20 ,  A61P25/26 ,  G01N33/15 ,  G01N33/566 ,  G01N33/94

Abstract: The present invention relates to a method of screening for a therapeutically useful compound which comprises testing an LC132 receptor agonist in a screening assay for psychiatric and/or neurological disorders. More particularly, the screening method is based on contacting an LC132 receptor with an agent suspected of being an agonist of the LC132 receptor function, followed by the detection of the binding and/or the agonist activity of the compound and then testing of an agent with LC132 agonist activity in an antiepileptic, anticonvulsant or anxiolytic screening assay.

公开(公告)号：HU9701032D0

公开(公告)日：1997-07-28

申请号：HU9701032

申请日：1997-06-11

Applicant: HOFFMANN LA ROCHE

Inventor： CIVELLI OLIVIER ,  MARTIN JAMES RICHARD ,  MONSMA FREDERICK ,  MOREAU JEAN-LUC ,  NOTHACKER HANS-PETER ,  REINSCHEID RAINER

IPC: G01N33/53 ,  A61K38/00 ,  A61K38/10 ,  A61P25/08 ,  A61P25/20 ,  A61P25/26 ,  G01N33/15 ,  G01N33/566 ,  G01N33/94

Abstract: The present invention relates to a method of screening for a therapeutically useful compound which comprises testing an LC132 receptor agonist in a screening assay for psychiatric and/or neurological disorders. More particularly, the screening method is based on contacting an LC132 receptor with an agent suspected of being an agonist of the LC132 receptor function, followed by the detection of the binding and/or the agonist activity of the compound and then testing of an agent with LC132 agonist activity in an antiepileptic, anticonvulsant or anxiolytic screening assay.